XM02 is superior to placebo and equivalent to Neupogen™ in reducing the duration of severe neutropenia and the incidence of febrile neutropenia in cycle 1 in breast cancer patients receiving docetaxel/doxorubicin chemotherapy

Peer Review reports

Original Submission
28 Apr 2008	Submitted	Original manuscript
2 Jun 2008	Author responded	Author comments - Heinz Lubenau
Resubmission - Version 2
2 Jun 2008	Submitted	Manuscript version 2
9 Jul 2008	Reviewed	Reviewer Report - Christian Chabannon
24 Jul 2008	Reviewed	Reviewer Report - Vassilis Georgoulias
Resubmission - Version 3
	Submitted	Manuscript version 3
1 Oct 2008	Author responded	Author comments - Heinz Lubenau
22 Oct 2008	Reviewed	Reviewer Report - Christian Chabannon
3 Nov 2008	Reviewed	Reviewer Report - Vassilis Georgoulias
Resubmission - Version 4
1 Oct 2008	Submitted	Manuscript version 4
Publishing
12 Nov 2008	Editorially accepted
12 Nov 2008	Article published	10.1186/1471-2407-8-332

Back to article page